Annals of internal medicine · 2025
Pharmacologic Treatment of Acute Attacks of Episodic Migraine: A Systematic Review and Network Meta-analysis for the American College of Physicians.
СтатьяСистематический обзорNetwork Meta-AnalysisНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Gartlehner Gerald, Dobrescu Andreea, Wagner Gernot, Chapman Andrea, Persad Emma, Nowak Claus, Klerings Irma, Neubauer Camilla, Feyertag Johanna, Gadinger Arianna, Thaler Kylie
Аннотация
BACKGROUND: Migraine is common, affecting 15% of Americans.
PURPOSE: To compare benefits and harms of pharmacologic treatments for acute attacks of episodic migraine in adults and assess cost-effectiveness.
DATA SOURCES: Three electronic databases searched to October 2024, gray literature, and reference lists.
STUDY SELECTION: Two investigators independently selected English-language randomized trials.
DATA EXTRACTION: Single reviewer data extraction with second review. Dual independent risk of bias and certainty of evidence (COE) assessment.
DATA SYNTHESIS: Twenty-one head-to-head and 165 placebo-controlled trials were included in meta-analyses and network meta-analyses. Triptans were more effective than acetaminophen (low COE) and nonsteroidal anti-inflammatory drugs (NSAIDs) (high COE) for pain outcomes at 2 hours and pain freedom up to 48 hours. Triptan and acetaminophen combinations were more effective than acetaminophen alone (moderate COE) for pain outcomes at 2 hours and pain freedom up to 48 hours but not more than triptans alone (low COE). Triptan and NSAID combinations were more effective for pain outcomes at 2 hours and pain freedom up to 48 hours compared with acetaminophen (low COE), gepants (low COE), NSAIDs (high COE), and triptan monotherapy (moderate COE). Triptan regimens, however, often had a higher risk for adverse events. One study found triptans more cost-effective than ditans and gepants.
LIMITATIONS: Harms assessment was limited to randomized trials. Many comparisons lacked sufficient evidence to draw conclusions.
CONCLUSION: Triptans and combinations of triptans were more effective than NSAID and acetaminophen alone.
PRIMARY FUNDING SOURCE: American College of Physicians. (PROSPERO: CRD42023441146).
PURPOSE: To compare benefits and harms of pharmacologic treatments for acute attacks of episodic migraine in adults and assess cost-effectiveness.
DATA SOURCES: Three electronic databases searched to October 2024, gray literature, and reference lists.
STUDY SELECTION: Two investigators independently selected English-language randomized trials.
DATA EXTRACTION: Single reviewer data extraction with second review. Dual independent risk of bias and certainty of evidence (COE) assessment.
DATA SYNTHESIS: Twenty-one head-to-head and 165 placebo-controlled trials were included in meta-analyses and network meta-analyses. Triptans were more effective than acetaminophen (low COE) and nonsteroidal anti-inflammatory drugs (NSAIDs) (high COE) for pain outcomes at 2 hours and pain freedom up to 48 hours. Triptan and acetaminophen combinations were more effective than acetaminophen alone (moderate COE) for pain outcomes at 2 hours and pain freedom up to 48 hours but not more than triptans alone (low COE). Triptan and NSAID combinations were more effective for pain outcomes at 2 hours and pain freedom up to 48 hours compared with acetaminophen (low COE), gepants (low COE), NSAIDs (high COE), and triptan monotherapy (moderate COE). Triptan regimens, however, often had a higher risk for adverse events. One study found triptans more cost-effective than ditans and gepants.
LIMITATIONS: Harms assessment was limited to randomized trials. Many comparisons lacked sufficient evidence to draw conclusions.
CONCLUSION: Triptans and combinations of triptans were more effective than NSAID and acetaminophen alone.
PRIMARY FUNDING SOURCE: American College of Physicians. (PROSPERO: CRD42023441146).